Novel Immunotherapy for Contact Dermatitis

Abstract (Set) Allergic contact dermatitis, the third most common reason for outpatient dermatology visits, is an immunological disease that gives significant influences on patient's quality of life and makes enormous economical impacts. Current therapies for contact dermatitis are largely dependent on general immunosuppressive drugs, which induce long-term destruction of immune system rendering patients immune-compromised. JHU scientists have identified a specific molecular pathway which plays an inhibitory role in the pathogenesis of contact dermatitis resulting in a novel therapy that selectively regulates a molecular pathway for allergen-specific immune responses, so that it prevents and treats contact dermatitis without non-specific immunosuppression. Description (Set) Proposed Use (Set) This invention implicates therapeutic efficacy of a new monoclonal antibody for contact dermatitis. Additional commercial applications include other forms of reagents to activate this pathway including small molecules, fusion proteins of counter ligands, DNA/RNA aptamers, small domain molecules, and small drugs.

Inventor(s): Tamada, Koji

Type of Offer: Licensing



« More Medical Patents

---